MedStar Washington Hospital Center
Welcome,         Profile    Billing    Logout  
 687 Trials 
811 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rizik, David G
NCT05149755: Evolut™ EXPAND TAVR II Pivotal Trial

Recruiting
N/A
650
Europe, Canada, Japan, US, RoW
Medtronic Evolut PRO+ TAVR System, or Evolut FX TAVR System, and guideline-directed management and therapy (GDMT)
Medtronic Cardiovascular
Moderate Aortic Valve Stenosis
02/26
12/34
Matthews, Ray
NCT02661451: Transcatheter Aortic Valve Replacement to UNload the Left Ventricle in Patients With ADvanced Heart Failure (TAVR UNLOAD)

Active, not recruiting
N/A
178
Europe, Canada, US
SAPIEN 3 THV, Optimal Heart Failure Therapy
Cardiovascular Research Foundation, New York, Cardialysis BV, Avania
Aortic Valve Stenosis
02/23
02/25
NCT05069558: Comparing PFO Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion

Recruiting
N/A
450
Europe, Canada, US
Investigational PFO Closure Device, Standard of Care PFO Closure Device
Occlutech International AB
Stroke, Patent Foramen Ovale
10/25
10/26
APOLLO, NCT03242642: Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.

Recruiting
N/A
1056
Europe, Canada, US
Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR)
Medtronic Cardiovascular
Mitral Valve Regurgitation
10/26
09/36
Yu, Wengui
CAPTIVA, NCT05047172: Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis

Recruiting
3
1683
US
Ticagrelor + Aspirin, Brilinta, Rivaroxaban + Aspirin, Xarelto, Clopidogrel + Aspirin, Plavix, Risk Factor Management
University of Florida, National Institute of Neurological Disorders and Stroke (NINDS), University of Cincinnati, Medical University of South Carolina, Janssen Scientific Affairs, LLC, AstraZeneca
Intracranial Arteriosclerosis, Stroke
05/27
05/27
Sabri, Saher
NCT05409976: The GORE® VIAFORT Vascular Stent IVC Study

Recruiting
N/A
111
Europe, US, RoW
GORE® VIAFORT Vascular Stent
W.L.Gore & Associates
Venous Thromboses, Venous Disease, Venous Leg Ulcer, Venous Stasis, Venous Ulcer, Venous Stenosis, Venous Occlusion, Vein Thrombosis, Vein Occlusion, Vein Disease
01/25
01/29
NCT05907564: Aventus Thrombectomy System Pulmonary Embolism Clinical Study

Recruiting
N/A
120
US
Thrombectomy
Inquis Medical, Inc.
Pulmonary Embolism, Embolism, Embolism and Thrombosis, Vascular Diseases, Cardiovascular Diseases, Lung Diseases, Respiratory Tract Diseases
03/25
03/25
NCT05489588: The GORE® VIAFORT Vascular Stent Iliofemoral Study

Recruiting
N/A
165
US
GORE® VIAFORT Vascular Stent
W.L.Gore & Associates
Venous Thromboses, Venous Disease, Venous Leg Ulcer, Venous Stasis, Venous Ulcer, Venous Stenosis, Venous Occlusion, Vein Thrombosis, Vein Occlusion, Vein Disease
04/25
04/29
DEFIANCE, NCT05701917: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis

Recruiting
N/A
300
Europe, US
ClotTriever System, Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc.
Inari Medical
Venous Thromboembolism, Deep Venous Thrombosis, Post-Thrombotic Syndrome
06/25
10/25
Kapadia, Samir
TWIST-EFS, NCT04919980: TVMR With the Innovalve System Trial - Early Feasibility Study

Recruiting
1
30
US
Innovalve MR system
Innovalve Bio Medical Ltd.
Mitral Valve Regurgitation (Degenerative or Functional)
09/24
09/28
NCT03904147: TRILUMINATE Pivotal Trial

Active, not recruiting
N/A
572
Europe, Canada, US
TriClipTM Device
Abbott Medical Devices
Tricuspid Regurgitation
11/22
04/29
NCT03173534: WATCH-TAVR, WATCHMAN for Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement

Completed
N/A
350
US
WATCHMAN, TAVR
samir kapadia, Boston Scientific Corporation, The Cleveland Clinic
Atrial Fibrillation, Aortic Valve Stenosis
12/22
12/22
CLASP IID, NCT03706833: Edwards PASCAL /IIF Pivotal Clinical Trial

Recruiting
N/A
1247
Europe, Canada, US
Edwards PASCAL System, Transcatheter Mitral Valve repair (TMVr), Abbott Mitraclip System
Edwards Lifesciences
Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation
01/25
04/30
NCT03735667: ACURATE IDE: Safety and Effectiveness Study of ACURATE Valve for Transcatheter Aortic Valve Replacement

Recruiting
N/A
2820
Canada, US
ACURATE neo2™ Transfemoral TAVR System, Medtronic CoreValve TAVR System, Edwards SAPIEN 3 TAVR System, ACURATE Prime™ Transfemoral TAVR System XL
Boston Scientific Corporation
Aortic Stenosis
06/24
11/34
SUMMIT, NCT03433274: Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation

Recruiting
N/A
958
Canada, US
Tendyne Mitral Valve System, MitraClip System
Abbott Medical Devices
Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Insufficiency, Cardiovascular Diseases, Valve Disease, Heart, Heart Valve Diseases, Functional Mitral Regurgitation, Degenerative Mitral Valve Disease
06/24
06/28
NCT05061004: Cephea Early Feasibility Study

Recruiting
N/A
30
Canada, US
Cephea Mitral Valve System
Abbott Medical Devices
Mitral Regurgitation
06/24
06/29
NCT04482062: TRISCEND II Pivotal Trial

Recruiting
N/A
1070
Europe, US
Edwards EVOQUE System, Transcatheter tricuspid valve replacement, Optimal Medical Therapy
Edwards Lifesciences
Tricuspid Valve Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease, Heart Valve Diseases, Cardiovascular Diseases, Heart Failure
06/24
12/29
NCT03142152: The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With at Least Mild FMR

Recruiting
N/A
300
Europe, US
Carillon Mitral Contour System, Carillon, Percutaneous mitral valve repair, Guideline Directed Heart Failure Medication
Cardiac Dimensions, Inc.
Functional Mitral Regurgitation, Heart Failure, Mitral Valve Insufficiency, Heart Diseases, Cardiovascular Diseases, Heart Valve Diseases
12/26
12/30
NCT04729933: Implantation of a Permanent Interatrial Shunt to Reduce Left Atrial Filling Pressures Following MitraClip

Recruiting
N/A
10
US
V-Wave Shunt Placement
samir kapadia, V-Wave Ltd
Heart Failure, Mitral Regurgitation
12/27
12/27
Moursi, Mohammed
APT.DFO.001, NCT05177107: Bacteriophage Therapy in Patients With Diabetic Foot Osteomyelitis

Recruiting
2b
126
US
Phage Therapy, Placebo
Adaptive Phage Therapeutics, Inc., United States Department of Defense
Osteomyelitis, Diabetic Foot Osteomyelitis
04/24
12/24
PL-5, NCT06189638: Phase II Study to Evaluate Efficacy and Safety of AMP Peptide in Mild Infections of Diabetic Foot Ulcers

Not yet recruiting
2
90
US
Antimicrobial Peptide PL-5 Topical Spray and Placebo, AMP PL-5 and Placebo
Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd., Parexel
Diabetic Foot Ulcers
12/24
06/25
JAGUAR, NCT05064540: Trial: ObJective Analysis to GaUge EVAR Outcomes Through Randomization

Recruiting
N/A
450
US
Alto Abdominal Stent Graft System, FDA Approved EVAR AAA Graft Systems
Endologix
AAA, AAA - Abdominal Aortic Aneurysm
12/28
12/28
DiBella, Nicholas
A011801, NCT04457596: T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

Calendar Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer
Recruiting
3
1031
Canada, US
Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.
Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Synchronous Bilateral Breast Carcinoma
01/28
05/35
CIRCULATE-US, NCT05174169: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Recruiting
2/3
1912
Canada, US
Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month
NRG Oncology, Natera, Inc., National Cancer Institute (NCI)
Stage III Colon Cancer
03/29
03/30
NCT04647916: Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases

Recruiting
2
44
US
Sacituzumab Govitecan, hRS7-SN38 Antibody Drug Conjugate, IMMU-132, RS7-SN38, Sacituzumab Govitecan-hziy, Trodelvy
SWOG Cancer Research Network, National Cancer Institute (NCI), Gilead Sciences
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic HER2 Negative Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Prognostic Stage IV Breast Cancer AJCC v8
02/25
12/26
Hutchinson, Mathew
NCT03168659: CardioFocus HeartLight Post-Approval Study

Recruiting
N/A
250
US
HeartLight, Ablation
CardioFocus
Atrial Fibrillation
10/24
10/26
NCT03970343: Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy

Recruiting
N/A
620
US
OPTIMIZER Smart System
Impulse Dynamics
Heart Failure
03/26
03/26
Morozov, Vadim
NCT05394662: Safety and Effectiveness of Juveena™ Hydrogel System Following TCGP At High-Risk for Intrauterine Adhesions

Recruiting
3
150
US
Juveena Hydrogel System
Rejoni Inc.
Intrauterine Adhesion
03/25
03/25
ELENA, NCT05560646: A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain

Recruiting
2
380
Europe, US, RoW
OG-6219, Placebo
Organon and Co, Iqvia Pty Ltd
Endometriosis
12/24
12/24
Mahmud, Ehtisham
NCT02661451: Transcatheter Aortic Valve Replacement to UNload the Left Ventricle in Patients With ADvanced Heart Failure (TAVR UNLOAD)

Active, not recruiting
N/A
178
Europe, Canada, US
SAPIEN 3 THV, Optimal Heart Failure Therapy
Cardiovascular Research Foundation, New York, Cardialysis BV, Avania
Aortic Valve Stenosis
02/23
02/25
COSIRA-II, NCT05102019: Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II

Recruiting
N/A
380
Canada, US
Arm 1: treatment with Neovasc Reducer, Arm 2 (control): Implantation procedure with no device implanted, Arm 3 (unblinded, non-randomized): Single arm registry
Neovasc Inc., Shockwave Medical, Inc.
Refractory Angina
06/24
12/28
ECLIPSE, NCT03108456: Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting StEnts: The Trial

Active, not recruiting
N/A
2005
US
Orbital Atherectomy, Balloon
Abbott Medical Devices, Cardiovascular Research Foundation, New York
Coronary Artery Disease, Ischemic Heart Disease, Non ST Segment Elevation Myocardial Infarction
06/24
06/25
TARGET-IV_NA, NCT04562532: Firehawk Rapamycin Target Eluting Coronary Stent North American Trial

Active, not recruiting
N/A
1720
Europe, Canada, US
Microport Firehawk stent, MicroPort Firehawk rapamycin target eluting stent, 2nd generation DES (XIENCE family, Promus family, Resolute/Onyx family/Endeavor, and Orsiro stent)
Shanghai MicroPort Medical (Group) Co., Ltd.
Coronary Artery Disease
06/24
06/27
ASPIRE PH, NCT04555161: Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System

Recruiting
N/A
30
US
Aria CV Pulmonary Hypertension System, Aria CV PH System
Aria CV, Inc
Pulmonary Arterial Hypertension, Pulmonary Hypertension, Right Heart Dysfunction
10/24
10/26
NCT03523416: Early Feasibility Study - Transcatheter Atrial Shunt System

Recruiting
N/A
75
US
Transcatheter Atrial Shunt System
Edwards Lifesciences
Heart Failure
12/24
12/26
PROTECT IV, NCT04763200: Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function

Recruiting
N/A
1252
Europe, Canada, US
Impella CP® / Impella CP® with SmartAssist® / Impella 2.5®, IABP Intra-aortic balloon pump
Abiomed Inc.
Left Ventricular Dysfunction, Coronary Artery Disease
03/26
10/27
Strouse, David
NCT06223789: VOLT-AF IDE Clinical Study

Recruiting
N/A
435
Europe, Canada, US, RoW
Pulsed Field Ablation
Abbott Medical Devices
Atrial Arrhythmia, Atrial Fibrillation, Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation
01/26
01/26
NCT03970343: Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy

Recruiting
N/A
620
US
OPTIMIZER Smart System
Impulse Dynamics
Heart Failure
03/26
03/26
Bailey, Lisa
PACES, NCT01349881: S0820, Adenoma and Second Primary Prevention Trial

Active, not recruiting
3
354
US
Eflornithine placebo & sulindac placebo, eflornithine & sulindac placebo, Eflornithine placebo & sulindac, Eflornithine plus sulindac
SWOG Cancer Research Network, National Cancer Institute (NCI), Cancer Prevention Pharmaceuticals, Inc.
Colorectal Neoplasms
02/27
02/32
A011801, NCT04457596: T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

Calendar Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer
Recruiting
3
1031
Canada, US
Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.
Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Synchronous Bilateral Breast Carcinoma
01/28
05/35
DRAMMATIC, NCT04071457: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

Hourglass Jan 2023 - Jun 2023 : From trial for patients with r/r multiple myeloma treated with an IMiD and PI
Recruiting
3
1100
Canada, US
Lenalidomide, CC-5013, Revlimid, Daratumumab/rHuPH20
SWOG Cancer Research Network, National Cancer Institute (NCI), Janssen, LP
Multiple Myeloma
07/29
07/40
CIRCULATE-US, NCT05174169: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Recruiting
2/3
1912
Canada, US
Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month
NRG Oncology, Natera, Inc., National Cancer Institute (NCI)
Stage III Colon Cancer
03/29
03/30
NCT03994796: Genetic Testing in Guiding Treatment for Patients With Brain Metastases

Recruiting
2
186
US
Abemaciclib, PI3K Inhibitor paxalisib, Entrectinib, Adagrasib, MRTX849
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Mirati Therapeutics Inc., Genentech, Inc., Eli Lilly and Company, Kazia Therapeutics Limited
CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, NTRK Family Gene Mutation, PI3K Gene Mutation, ROS1 Gene Mutation, KRAS G12C Mutation
10/24
06/25
NCT04647916: Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases

Recruiting
2
44
US
Sacituzumab Govitecan, hRS7-SN38 Antibody Drug Conjugate, IMMU-132, RS7-SN38, Sacituzumab Govitecan-hziy, Trodelvy
SWOG Cancer Research Network, National Cancer Institute (NCI), Gilead Sciences
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic HER2 Negative Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Prognostic Stage IV Breast Cancer AJCC v8
02/25
12/26
Ahmed, Sara
NCT04464785: CentriMag Failure-to-Wean Post Approval Study

Recruiting
N/A
32
US
CentriMag Circulatory Support System
Abbott Medical Devices
Heart Failure
12/24
01/25
Wilky, Breelyn
MOTION, NCT05059262: Study of Vimseltinib for Tenosynovial Giant Cell Tumor

Active, not recruiting
3
120
Europe, Canada, US, RoW
vimseltinib, DCC-3014, Placebo
Deciphera Pharmaceuticals LLC
Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath, Tenosynovial Giant Cell Tumor, Diffuse, Tenosynovial Giant Cell Tumor, Localized
08/23
07/26
SARC041, NCT04967521: Study of Abemaciclib Versus Placebo in Patients With Advanced Dedifferentiated Liposarcoma

Recruiting
3
108
US
Abemaciclib, LY2835219, Placebo
Sarcoma Alliance for Research through Collaboration, Eli Lilly and Company
Advanced Dedifferentiated Liposarcoma
05/24
11/24
ARGSARC, NCT05712694: Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma

Recruiting
3
300
Canada, US, RoW
ADI PEG20, Pegargiminase, Placebo
Polaris Group
Soft Tissue Sarcoma
12/27
12/27
SPEARHEAD-1, NCT04044768: Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Checkmark Data from cohort 1 of SPEARHEAD-1 trial for synovial sarcoma or myxoid round cell liposarcoma
Nov 2022 - Nov 2022: Data from cohort 1 of SPEARHEAD-1 trial for synovial sarcoma or myxoid round cell liposarcoma
Checkmark Pooled analysis data from trials for sarcoma at AACR 2022
Jun 2022 - Jun 2022: Pooled analysis data from trials for sarcoma at AACR 2022
Checkmark From SPEARHEAD 1 trial for synovial sarcoma or myxoid/round cell liposarcoma
More
Recruiting
2
120
Europe, Canada, US
afamitresgene autoleucel (previously ADP-A2M4)
Adaptimmune
Synovial Sarcoma, Myxoid Liposarcoma
10/21
04/38
NCT04028063: Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas

Recruiting
2
28
US
doxorubicin with AGEN1884 and AGEN2034
University of Colorado, Denver, Agenus Inc.
Metastatic Soft Tissue Sarcoma, Advanced Soft Tissue Sarcoma
11/24
11/25
ChonDRAgon, NCT04950075: Study of INBRX-109 in Conventional Chondrosarcoma

Recruiting
2
201
Europe, US, RoW
INBRX-109, Placebo
Inhibrx, Inc.
Conventional Chondrosarcoma
12/24
06/25
NCT04551430: Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma

Active, not recruiting
2
105
US
Cabozantinib, Nivolumab, Opdivo, Ipilimumab, Yervoy
Washington University School of Medicine, Exelixis, Bristol-Myers Squibb
Metastatic Soft-tissue Sarcoma
06/25
06/30
IMC-C103C-101, NCT03973333: Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab

Terminated
1/2
75
Europe, US
IMC-C103C, Atezolizumab, TECENTRIQ
Immunocore Ltd
Select Advanced Solid Tumors
09/23
09/23
DCC-3014-01-001, NCT03069469: Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor

Active, not recruiting
1/2
120
Europe, Canada, US, RoW
Vimseltinib, DCC-3014
Deciphera Pharmaceuticals LLC
Advanced Malignant Neoplasm, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath, Tenosynovial Giant Cell Tumor, Tenosynovial Giant Cell Tumor, Diffuse
07/26
08/28
BA3011-001, NCT03425279: CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma

Recruiting
1/2
300
US, RoW
CAB-AXL-ADC, PD-1 inhibitor
BioAtla, Inc.
Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma
12/24
12/24
NCT06156410: Cabozantinib With Ifosfamide in Ewing's Sarcoma and Osteosarcoma

Recruiting
1
30
US
Cabozantinib
Children's Hospital of Philadelphia, Children's Hospital Colorado, Exelixis, Alex's Lemonade Stand Foundation
Ewing Sarcoma, Osteosarcoma
11/27
11/28
NCT05108623: A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid Tumors

Completed
1
34
US
agenT-797, Approved ICIs
MiNK Therapeutics
Tumor, Solid
01/24
01/24
C-800-01, NCT03860272: Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

Recruiting
1
550
Europe, US
Botensilimab, AGEN1181, Anti-CTLA-4, Balstilimab, AGEN2034, Anti-PD-1
Agenus Inc.
Advanced Cancer, Angiosarcoma, Colorectal Cancer Without Liver Metastases, Endometrial Cancer, Fibrolamellar Carcinoma, Non-small-cell Lung Cancer, Ovarian Cancer, Prostate Cancer
 
 
Gulati, Anthony
NCT04025372: INTREPId (INTermediate Risk Erection PreservatIon Trial)

Recruiting
2
220
US
Bicalutamide, GnRH Agonist, Radiation Therapy, Darolutamide
Dana-Farber Cancer Institute, Bayer, Decipher Biosciences
Prostate Cancer
03/25
03/28
Cheng, David
stAAAble, NCT06001918: Nectero EAST System Clinical Study

Recruiting
2/3
400
US
Nectero EAST System
Nectero Medical, Inc.
Abdominal Aortic Aneurysm
03/27
12/29
NCT04514861: Monitoring Local Tissue Oxygen Changes Using the Wireless Lumee Oxygen Platform in Correlation to TcPO2

Recruiting
N/A
53
US
Wireless Lumee Oxygen Platform
Profusa, Inc., National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI)
Peripheral Artery Disease
12/21
05/22
Rapisuwon, Suthee
HCRN-MEL17-309, NCT03528408: Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma

Active, not recruiting
2
52
US
Nivolumab, Opdivo, Ipilimumab, Yervoy
Suthee Rapisuwon, Bristol-Myers Squibb
Melanoma, Ocular Melanoma
05/23
06/23
Neo-MEL-T, NCT04139902: Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma

Recruiting
2
56
US
Dostarlimab (TSR-042) (singly), Dostarlimab, Dostarlimab (TSR-042) and TSR-022 (combination)
Diwakar Davar, Tesaro, Inc.
Melanoma Stage III, Melanoma Stage IV
09/25
04/29
XTX202-01, NCT05052268: XTX202 in Patients With Advanced Solid Tumors

Active, not recruiting
1/2
189
US
XTX202
Xilio Development, Inc.
Advanced Solid Tumor
02/26
02/26
Goyal, Munish
REVERSE-IT, NCT04286438 / 2019-004457-92: Bentracimab in Ticagrelor-treated Patients With Uncontrolled Bleeding or Requiring Urgent Surgery or Invasive Procedure

Recruiting
3
200
Europe, Canada, US, RoW
Bentracimab (PB2452) Infusion
SFJ Pharmaceuticals, Inc.
Hemorrhage, Urgent Surgery, Invasive Procedure
08/24
08/24
Willey, Shawna C
NCT01570998: Intraoperative Radiation Therapy in Treating Patients With Breast Cancer Undergoing Breast-Conserving Surgery

Recruiting
N/A
1500
US
Intraoperative Radiation Therapy, Intraoperative Radiotherapy, IORT, radiotherapy, intraoperative, Laboratory Biomarker Analysis
University of California, San Francisco, Carl Zeiss Meditec AG
Stage IA Breast Cancer, Stage IIA Breast Cancer
12/27
12/27
Mohammed, Selma
ALLEVIATE-HF, NCT04452149: Algorithm Using LINQ Sensors for Evaluation And Treatment of Heart Failure

Recruiting
N/A
900
US
Reveal LINQ™ Insertable Cardiac Monitor with investigational ALLEVIATE-HF RAMware download, Medication intervention
Medtronic Cardiac Rhythm and Heart Failure
Heart Failure NYHA Class II, Heart Failure NYHA Class III
04/25
04/25
Sheikh, Farooq
VENUS-HF, NCT03836079: SVC Occlusion in Subjects With Acute Decompensated Heart Failure

Recruiting
N/A
100
US
preCARDIA system
Abiomed Inc.
Acute Decompensated Heart Failure, Acute Heart Failure, Congestive Heart Failure, Heart Diseases
07/24
10/24
Schuster, Steven R
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Active, not recruiting
3
900
Europe, Canada, Japan, US, RoW
Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib
Eli Lilly and Company
Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
02/24
10/27
NCT05028348 / 2021-001691-41: A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma

Calendar Jul 2024 - Dec 2024: Top-line data from XPORT-MM-031 trial in combination with pomalidomide and dexamethasone for multiple myeloma
Jun 2023 - Dec 2023: Completion of enrolment of trial in combination with pomalidomide and dexamethasone for multiple myeloma
Recruiting
3
222
Europe, US
Selinexor, KPT-330, Elotuzumab, Pomalidomide, Dexamethasone Oral
Stichting European Myeloma Network, Karyopharm Therapeutics Inc
Multiple Myeloma
03/26
03/29
PACES, NCT01349881: S0820, Adenoma and Second Primary Prevention Trial

Active, not recruiting
3
354
US
Eflornithine placebo & sulindac placebo, eflornithine & sulindac placebo, Eflornithine placebo & sulindac, Eflornithine plus sulindac
SWOG Cancer Research Network, National Cancer Institute (NCI), Cancer Prevention Pharmaceuticals, Inc.
Colorectal Neoplasms
02/27
02/32
KEYNOTE-E02, NCT03485209 / 2017-005076-26: Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors

Recruiting
2
692
Europe, Canada, US
tisotumab vedotin, TIVDAK, pembrolizumab, KEYTRUDA®, carboplatin, cisplatin
Seagen Inc., Genmab, Merck Sharp & Dohme LLC
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck
04/25
11/26
NCT04963283: Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer

Active, not recruiting
2
48
US
Cabozantinib, Cabometyx, Nivolumab, Opdivo
University of Colorado, Denver, National Cancer Institute (NCI), Criterium, Inc., Bristol-Myers Squibb, Exelixis
Colorectal Adenocarcinoma, Colon Cancer, Colon Adenocarcinoma, Rectum Cancer, Rectal Cancer, Rectal Adenocarcinoma, Colorectal Cancer
02/25
02/26
Tesfaye, Anteneh A
ACTION-1, NCT05477576: Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

Active, not recruiting
3
288
Europe, Canada, US, RoW
RYZ101, Everolimus 10 mg, Sunitinib 37.5 MG, Octreotide LAR 60 MG Injection, Lanreotide 120Mg Sa Susp Inj Syringe
RayzeBio, Inc.
GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors, Carcinoid, Carcinoid Tumor, Pancreatic NET
07/25
07/28
AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Recruiting
3
711
Europe, Canada, Japan, US, RoW
Dostarlimab, CAPEOX, FOLFOX
GlaxoSmithKline
Colonic Neoplasms, Neoplasms, Colon
12/28
12/30
AZUR-1, NCT05723562 / 2022-003289-18: A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer

Recruiting
2
150
Europe, Canada, Japan, US, RoW
Dostarlimab, JEMPERLI, dostarlimab-gxly, TSR-042, GSK4057190A
GlaxoSmithKline, GlaxoSmithKline Research & Development Ltd
Neoplasms, Rectal
11/26
10/29
NCT05189171: MicroOrganoSphere (MOS) Drug Screen Pilot Trial in Colorectal Cancer

Completed
N/A
46
US
MicroOrganoSphere (MOS) drug screen
Xilis, Inc.
Colorectal Neoplasms
11/23
03/24
Prete, Salvatore A Del
ASTRIDE, NCT05468489: To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

Recruiting
3
200
US
Serplulimab + chemotherapy (carboplatin-etoposide), Atezolizumab + chemotherapy (carboplatin-etoposide)
Shanghai Henlius Biotech
Extensive Stage Small Cell Lung Cancer
10/24
12/25
SWOG S2302, NCT05633602: Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

Recruiting
3
700
US
Chemotherapy, Chemo, Chemotherapy (NOS), Chemotherapy, Cancer, General, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Ramucirumab, Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, IMC-1121B, LY3009806
SWOG Cancer Research Network, National Cancer Institute (NCI), Eli Lilly and Company, Merck Sharp & Dohme LLC
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
03/25
03/28
Rabinovitch, Rachel A
PREDICT, NCT03448926: The Registry for DCIS Patients With DCISionRT Testing

Suspended
N/A
2500
US, RoW
Treatment Recommendation Surveys
PreludeDx, University of South Florida
DCIS
11/25
11/35
Robinson, James
NCT05394662: Safety and Effectiveness of Juveena™ Hydrogel System Following TCGP At High-Risk for Intrauterine Adhesions

Recruiting
3
150
US
Juveena Hydrogel System
Rejoni Inc.
Intrauterine Adhesion
03/25
03/25
AOST-2121, NCT04974008: Osteosarcoma Maintenance Therapy With OST31-164

Completed
2
39
US
OST31-164
George Clinical Pty Ltd
Bone Cancer
09/23
09/23
Slack, Michael
CLASP IID, NCT03706833: Edwards PASCAL /IIF Pivotal Clinical Trial

Recruiting
N/A
1247
Europe, Canada, US
Edwards PASCAL System, Transcatheter Mitral Valve repair (TMVr), Abbott Mitraclip System
Edwards Lifesciences
Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation
01/25
04/30
Durrani, Sarfraz
NCT05227053: STOP AF First Post-Approval Study

Recruiting
N/A
200
US
Arctic Front™ Cardiac Cryoablation Catheter
Medtronic Cardiac Rhythm and Heart Failure
Paroxysmal Atrial Fibrillation
01/28
01/28
Nahab, Fadi
CAPTIVA, NCT05047172: Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis

Recruiting
3
1683
US
Ticagrelor + Aspirin, Brilinta, Rivaroxaban + Aspirin, Xarelto, Clopidogrel + Aspirin, Plavix, Risk Factor Management
University of Florida, National Institute of Neurological Disorders and Stroke (NINDS), University of Cincinnati, Medical University of South Carolina, Janssen Scientific Affairs, LLC, AstraZeneca
Intracranial Arteriosclerosis, Stroke
05/27
05/27
Rammohan, Chad
NCT03904147: TRILUMINATE Pivotal Trial

Active, not recruiting
N/A
572
Europe, Canada, US
TriClipTM Device
Abbott Medical Devices
Tricuspid Regurgitation
11/22
04/29
APOLLO, NCT03242642: Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.

Recruiting
N/A
1056
Europe, Canada, US
Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR)
Medtronic Cardiovascular
Mitral Valve Regurgitation
10/26
09/36
Pokharel, Shreejana
NCT02438306: CardiAMP™ Cell Therapy for Heart Failure Trial

Active, not recruiting
3
125
Canada, US
Autologous cell therapy, Sham
BioCardia, Inc.
Heart Failure, Systolic
12/24
12/26
Eldadah, Zayd
NCT04431544: AcQMap® US Registry of Procedural and Long-term Clinical Outcomes (Discover-US)

Terminated
N/A
513
US
AcQMap System
Acutus Medical
Ablation of Arrhythmia's
11/23
11/23
Deressa, Meseret
CHANGE AFIB, NCT05130268: Early Dronedarone Versus Usual Care to Improve Outcomes in Persons With Newly Diagnosed Atrial Fibrillation

Active, not recruiting
4
3000
US
Dronedarone, Multaq
American Heart Association, Duke Clinical Research Institute, Sanofi
Atrial Fibrillation
06/24
12/24
NCT03970343: Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy

Recruiting
N/A
620
US
OPTIMIZER Smart System
Impulse Dynamics
Heart Failure
03/26
03/26
Coordinator, Research
NCT05078827: Therapeutic Equivalence of Fluorouracil Cream, 5% Compared With Fluorouracil 5% Topical Cream of MylanPharmaceuticals Inc., U.S.A in the Treatment of Actinic Keratosis

Completed
3
458
US
Test Product (A): Fluorouracil Cream, 5% topical cream, Experimental, Reference Product (B): Fluorouracil 5% Topical Cream of Mylan Pharmaceuticals Inc., Morgantown, WV 26505 U.S.A., Active Comparator, Placebo Product (C): Test vehicle cream for fluorouracil 5% of Encube Ethicals Pvt. Ltd., India, Placebo Comparator
Encube Ethicals Pvt. Ltd., CBCC Global Research
Actinic Keratoses
11/22
12/22
ReMMi-D, NCT05853900: Study of Two Digital Therapeutics for the Prevention of Episodic Migraine

Completed
3
558
US
ReMMi-D Digital Therapeutic
Click Therapeutics, Inc.
Migraine, Episodic Migraine, Headache, Headache, Migraine
05/24
05/24
OPERA-T, NCT05238116 / 2021-004554-32: Safety and Efficacy of PC945 (Opelconazole) in Combination With Other Antifungal Therapy for the Treatment of Refractory Invasive Pulmonary Aspergillosis ( Study)

Recruiting
3
123
Europe, Canada, US, RoW
PC945, Placebo
Pulmocide Ltd
Refractory IPA
03/25
04/25
NCT06004388: Study of Two Digital Therapeutics for the Prevention of Episodic Migraine Receiving CGRP Therapy (ReMMiD-C)

Active, not recruiting
3
110
US
Click Digital Therapeutic
Click Therapeutics, Inc.
Migraine, Episodic Migraine, Headache, Headache, Migraine
05/24
06/24
CONVOKE, NCT05838625: Study of Two Digital Therapeutics for the Treatment of Experiential Negative Symptoms of Schizophrenia

Recruiting
3
432
US
Digital Therapeutic
Click Therapeutics, Inc., Boehringer Ingelheim
Schizophrenia
06/25
07/25
NCT06067984: An Extension Study of a Second Course of a Digital Therapeutic for the Treatment of Experiential Negative Symptoms of Schizophrenia

Recruiting
3
216
US
Study App
Click Therapeutics, Inc., Boehringer Ingelheim
Schizophrenia, Negative Symptoms in Schizophrenia
09/24
10/24
NCT06365437: A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantation

Recruiting
2
40
Europe
TCD601, Siplizumab, Tacrolimus (TAC), Corticosteroids (CS), Mycophenolate Mofetil (MMF), ATG
ITB-Med LLC
Kidney Transplantation
08/25
08/25
PHYOX8, NCT05001269 / 2021-001083-16: Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function

Recruiting
2
25
Europe, Canada, Japan, US, RoW
nedosiran, DCR-PHXC
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Primary Hyperoxaluria, Primary Hyperoxaluria Type 1, Primary Hyperoxaluria Type 2, Primary Hyperoxaluria Type 3
12/24
12/24
CHASE, NCT05727878: Trial to Evaluate Safety and Efficacy of KPI-012 Ophthalmic Solution in Participants With PCED

Recruiting
2
2
US
KPI-012, KPI-012 Vehicle
Combangio, Inc, Kala Pharmaceuticals, Inc.
Persistent Corneal Epithelial Defect
02/24
08/24
 

Download Options